Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

  1. Vivek Naranbhai
  2. Kerri J. St. Denis
  3. Evan C. Lam
  4. Onosereme Ofoman
  5. Wilfredo F. Garcia-Beltran
  6. Cristhian B. Mairena
  7. Atul K. Bhan
  8. Justin F. Gainor
  9. Alejandro B. Balazs
  10. A. John Iafrate
  11. Ryan J. Sullivan
  12. Aditya Bardia
  13. Laura M. Spring
  14. Steven J. Isakoff
  15. Jocelyn R. Farmer
  16. Leyre Zubiri
  17. Gabriella S. Hobbs
  18. Joan How
  19. Andrew M. Brunner
  20. Amir T. Fathi
  21. Clarie A. Pernat
  22. A. Gavralidis
  23. Jennifer L. Peterson
  24. Mustafa Sakhi
  25. Grace Hambelton
  26. Elyssa N. Denault
  27. Lindsey J. Mortensen
  28. Lailoo A. Periello
  29. Marissa N. Bruno
  30. M.N. Bruno
  31. Brittany Y. Betraux
  32. Alyssa R. Lawless
  33. Melissa A. Jackson
  34. Elizabeth Niehoff
  35. Claire Barabell
  36. Christain N. Nambu
  37. Erika Nakajima
  38. Thomas Reinecke
  39. Cyndi Bowes
  40. Grace E. Kirkpatrick
  41. Julia C. Thierauf
  42. Kerri Reynolds
  43. Henning Willers
  44. Anand S. Dighe
  45. Rebecca Saff
  46. Kimberley Blumenthal

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ccell.2021.12.002
  2. ScreenIT

    SciScore for 10.1101/2021.11.10.21265988: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This study was approved by the Mass General Brigham Human Research Committee (2021P000746).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    For this analysis we randomly selected participants without prior SARS CoV-2 infection (confirmed by anti-nucleocapsid antibody testing) who had received each of the three FDA EUA vaccines (by allocating random numbers to each participant and selecting the first 60).
    anti-nucleocapsid
    suggested: None
    Anti-receptor binding domain antibodies were measured with an enzyme-linked immunosorbent assay (ELISA) that we have previously described.
    Anti-receptor binding domain
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    In brief, pseudovirus neutralization titer 50 (pNT50) was calculated by taking the inverse of the serum concentration that achieved 50% neutralization of SARS-CoV-2 pseudotyped lentivirus particles entry into ACE2 expressing 293T cells.
    293T
    suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)
    Software and Algorithms
    SentencesResources
    Figures were rendered in GraphPad Prism v9.0.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This may be a helpful threshold in counselling patients regarding need for boosters, notwithstanding limitations of inferring clinical protection from immunologic measures. A key limitation of this study is the focus on in vitro immunogenicity. Effectiveness of vaccines against variants is likely to be more complex involving differences in viral infectivity, exposure rates, transmissibility and possibly virulence in combination with largely humoral immune responses and cellular responses. This is illustrated by the exceptional success of the delta variant in transmission, but its relatively modest escape of neutralization. The number of individuals evaluated after booster doses is modest, but these represent the extra tail of the curve of patients who failed to make adequate responses after initial vaccination. In conclusion, while current wildtype-based SARS CoV-2 vaccines induce lower magnitude responses in patients with cancer that show impaired neutralization of viral variants, boosting these responses can safely restore breadth against current viral variants.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.11.10.21265988v1 on medRxiv